Art

J-GLOBAL ID：201802291260515200   Reference number：18A1141169

New development in CAR-T cell therapy

CAR-T細胞療法における新しい開発【JST・京大機械翻訳】

Author (4)： Wang Zhenguang (Molecular & Immunological Department, Bio-therapeutic Department, Chinese PLA General Hospital, Beijing, China) ,  Wu Zhiqiang (Molecular & Immunological Department, Bio-therapeutic Department, Chinese PLA General Hospital, Beijing, China) ,  Liu Yang (Department of Geriatric Hematology, Chinese PLA General Hospital, Beijing, China) ,  Han Weidong (Molecular & Immunological Department, Bio-therapeutic Department, Chinese PLA General Hospital, Beijing, China)
Material： Journal of Hematology & Oncology (Web)
Volume： 10  Issue： 1  Page： 53  Publication year： 2017 
JST Material Number： U7517A  ISSN： 1756-8722  Document type： Article
Article type： 文献レビュー  Country of issue： United Kingdom (GBR)  Language： ENGLISH (EN)

Abstract/Point： Chimeric antigen receptor (CAR...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=18A1141169&from=J-GLOBAL&jstjournalNo=U7517A") }}

Thesaurus term： *cell transplantation ,  tumor ,  adoptive immunotherapy ,  tumor antigen ,  recurrence ,  antigen ,  immunotherapy ,  safety ,  *T cell ,  solid tumor
Semi thesaurus term： キメラ抗原受容体 ,  完全寛解 ,  CD19抗原 ,  急性リンパ性白血病 ,  悪性腫瘍 , 【Automatic Indexing@JST】

Author keywords (5)： Chimeric antigen receptor ,  CAR-T ,  Engineered T cells ,  Adoptive cell therapy ,  Cancer treatment

JST classification (2)： Immunotherapy for tumors  (GE03035B) ,  Blood cell tumors(=neoplasms)  (GK04000M)

Reference (94)：

• Handb Exp Pharmacol; The T-body approach: redirecting T cells with antibody specificity; Z Eshhar; 181; 2008; 329-42; 10.1007/978-3-540-73259-4_14; CR1;
• J Gene Med; Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions; KJ Curran, HJ Pegram, RJ Brentjens; 14; 6; 2012; 405-15; 10.1002/jgm.2604; CR2;
• Dai H, Wang Y, Lu X, Han W. Chimeric antigen receptors modified T-cells for cancer therapy. J Natl Cancer Inst. 2016;108(7):djv439.
• Proc Natl Acad Sci U S A; Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors; Z Eshhar, T Waks, G Gross, DG Schindler; 90; 2; 1993; 720-4; 10.1073/pnas.90.2.720; CR4;
• J Clin Invest; CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients; CJ Turtle, LA Hanafi, C Berger, TA Gooley, S Cherian, M Hudecek, D Sommermeyer, K Melville, B Pender, TM Budiarto; 126; 6; 2016; 2123-38; 10.1172/JCI85309; CR5;

Terms in the title (2)： CAR-T細胞療法 ,  開発